The Federal Drug Administration (FDA) sent warnings to Ranbaxy, a generic drug company based in India, partially restricting imports of some drugs while it was highly critical of the company's sloppy quality control for others. Redactions in the letters make it impossible to know whether the problems cited apply to the anti-anxiety and anti-depressants Ranbaxy makes.
While the FDA was coming down on Ranbaxy, Rep. John Dingell, chair of the House Committee on Energy and Commerce, released a statement asking why the watchdog agency waited three years after learning "Ranbaxy had engaged in a pattern of fraudulent behavior regarding its generic drug applications and [the] records pertaining to good manufacturing practices."
Ranbaxy's website asks, "are generic drugs as safe and effective as branded drugs?" Read the FDA's letters and judge for yourself. A list of their products includes numerous drugs.
